Replies to post #107145 on Biotech Values

[biomaven0]

>Aria

That prompted me to check the clinical trials site. There seem to be 3 new rida trials in the last few months:

Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
This study is currently recruiting participants.
Verified by Brown University, September 2010
First Received: September 29, 2010

The following is a combo with an HDAC inhibitor - the idea is that HDAC inhibition seems to amplify the effect of inhibiting mTor.

A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Renal Cell Carcinoma (RCC)
This study is not yet open for participant recruitment.
Verified by Fox Chase Cancer Center, July 2010
First Received: July 22, 2010

And they haven't given up on breast - this is a combo with their mAb against insulin-like growth factor-1 (IGF-1) receptor (IGF1R). This is promising in theory because inhibiting mTor by itself seems to upregulate the IGF-1R/PI3K/Akt pathway, which is one of the key pathways upregulated in breast ca.

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
This study is currently recruiting participants.
Verified by Merck, October 2010
First Received: October 12, 2010 Last Updated: October 13, 2010 History of Changes
Sponsor: Merck
Information provided by: Merck
ClinicalTrials.gov Identifier: NCT01220570
Purpose

This clinical trial will evaluate whether treatment with ridaforolimus, dalotuzumab, or ridforolimus/dalotuzumab combination therapy reduces Growth Factor Signature (GFS) Score among participants with breast cancer.